Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001209191-20-004717)

Filing Details

Accession Number:: 0001209191-20-004717
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-01-23 17:33:48
Reporting Period:: 2020-01-21

Accepted Time:: 2020-01-23 17:33:48
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1328143	Adamas Pharmaceuticals Inc	ADMS	Pharmaceutical Preparations (2834)	421560076

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1717583	B Christopher Prentiss	C/O Adamas Pharmaceuticals, Inc. 1900 Powell St., Suite 1000 Emeryville CA 94608	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-01-21	1,269	$5.92	70,940	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Footnotes

Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units.
The shares were sold at prices ranging from $5.90 to $5.93. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.